Research Report for: Gilead Sciences Inc. (NASDAQ:GILD)


Gilead Sciences Inc. (NASDAQ:GILD) will report its next earnings on 7-Feb-17. The company reported the earnings of $2.75/Share in the last quarter where the estimated EPS by analysts was $2.86/share. The difference between the expected and actual EPS was $-0.11/share, which represents an Earnings surprise of -3.8%.

Many analysts are providing their Estimated Earnings analysis for Gilead Sciences Inc. and for the current quarter 22 analysts have projected that the stock could give an Average Earnings estimate of $2.62/share. These analysts have also projected a Low Estimate of $2.36/share and a High Estimate of $2.94/share.

In case of Revenue Estimates, 21 analysts have provided their consensus Average Revenue Estimates for Gilead Sciences Inc. as 7.16 Billion. According to these analysts, the Low Revenue Estimate for Gilead Sciences Inc. is 6.66 Billion and the High Revenue Estimate is 7.62 Billion. The company had Year Ago Sales of 8.51 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for GILD to be -21.1%. They are projecting Next Quarter growth of -14.2%. For the next 5 years, Gilead Sciences Inc. is expecting Growth of -2.31% per annum, whereas in the past 5 years the growth was 66.85% per annum.

Some buy side analysts are also providing their Analysis on Gilead Sciences Inc., where 6 analysts have rated the stock as Strong buy, 11 analysts have given a Buy signal, 11 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. 22 Analysts reported that the Price Target for Gilead Sciences Inc. might touch $118 high while the Average Price Target and Low price Target is $95.01 and $74.29 respectively.

To analyze a stock, one should look for Upgrades and Downgrades of a stock. Gilead Sciences Inc. got Initiated on 14-Nov-16 where investment firm Stifel Initiated the stock to Buy.

Gilead Sciences Inc. closed its last trading session at $72.13 with the loss of -0.78%. The Market Capitalization of the company stands at 94.66 Billion. The Company has 52-week high of $103.1 and 52-week low of $70.83. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -3.07% where SMA50 and SMA200 are -3.32% and -10.63% respectively. The Company Touched its 52-Week High on Apr 26, 2016 and 52-Week Low on Dec 8, 2016.

The Relative Volume of the company is 1.01 and Average Volume (3 months) is 9.7 million. Gilead Sciences Inc. P/E (price to earnings) ratio is 6.64 and Forward P/E ratio of 6.63.

The company shows its Return on Assets (ROA) value of 29.3%. The Return on Equity (ROE) value stands at 93.7%. While it’s Return on Investment (ROI) value is 45.9%.

While looking at the Stock’s Performance, Gilead Sciences Inc. currently shows a Weekly Performance of -2.98%, where Monthly Performance is -3.41%, Quarterly performance is -1.88%, 6 Months performance is -16.38% and yearly performance percentage is -19.13%. Year to Date performance value (YTD perf) value is -0.06%. The Stock currently has a Weekly Volatility of 1.31% and Monthly Volatility of 1.73%.